Diabetes drug liraglutide linked to lower risk of cardiovascular events

December 5, 2018, Karolinska Institutet

Real world data from a large Nordic study shows that use of liraglutide, a drug for type 2 diabetes, is associated with a lower risk of myocardial infarction, stroke or cardiovascular death. The study, led by researchers from Karolinska Institutet in Sweden, is published in The Lancet Diabetes & Endocrinology.

The number of with type 2 diabetes is increasing rapidly in the world. Cardiovascular disease is a serious complication of diabetes and represents a major cause of mortality in this patient group.

Liraglutide, a diabetes medication, became available for clinical use in 2009. This is a glucagon-like peptide 1 receptor agonist that lowers blood sugar and reduces body weight. A large clinical trial published previously showed that liraglutide reduced the risk of major cardiovascular events among patients with diabetes who had established or were at high cardiovascular risk. It has been unclear if these findings also translate to cardiovascular benefit in the broad patient population seen in routine clinical practice.

The current study was a collaborative project between researchers at Karolinska Institutet in Sweden, Statens Serum Institut in Denmark, NTNU in Norway and the Swedish National Diabetes Register. The researchers used several nationwide registers with information on , diseases and other data from more than 46,000 patients in Sweden and Denmark, 2010-2016.

Around 23,000 patients initiating treatment with liraglutide were compared with the same number of patients initiating treatment with another drug, DPP4 inhibitors. The main outcome in the study was major cardiovascular events, defined as myocardial infarction, stroke, or .

The rate of major cardiovascular events was 14.0 per 1,000 person-years among patients using liraglutide and 15.4 per 1,000 among patients using DPP4 inhibitors, a statistically significant difference. This corresponded to 5 fewer major cardiovascular events per 1,000 patients followed up for 3 years.

Use of liraglutide was also associated with reduced risk of cardiovascular death and any cause of death. In a subgroup analysis, patients with a history of major cardiovascular disease appeared to benefit most from treatment with liraglutide, although this was not a statistically compared with patients without such history.

"Our study provides support for the cardiovascular effectiveness of liraglutide among a broader unselected group of patients, providing important confirmatory evidence from routine clinical practice. We believe it may be of interest to drug regulators, clinical guidelines, physicians, and patients," says last author Björn Pasternak, senior researcher at the Department of Medicine, Solna, Karolinska Institutet, and affiliated with Statens Serum Institut.

Explore further: Liraglutide not tied to higher risk of cardiovascular events

More information: "Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden". Henrik Svanström, Peter Ueda, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn Pasternak. The Lancet Diabetes & Endocrinology, online 5 December 2018, DOI: 10.1016/S2213-8587(18)30320-6

Related Stories

Liraglutide not tied to higher risk of cardiovascular events

October 13, 2017
(HealthDay)—Liraglutide treatment for weight management is not associated with increased risk of cardiovascular events, according to a study published online Sept. 26 in Diabetes, Obesity and Metabolism.

Albiglutide reduces cardiovascular events in patients with type 2 diabetes and existing cardiovascular disease

October 2, 2018
New research presented at this year's annual meeting of the European Association for the Study of Diabetes (EASD) and published in The Lancet shows that treatment with albiglutide (a type of drug called a glucagon-like peptide ...

New medications for diabetes management have additional heart benefits, study finds

August 27, 2018
A drug used to manage diabetes may reduce heart disease and death in people with diabetes regardless of their cholesterol levels and whether they are on a statin therapy, suggests a new analysis of the LEADER trial.

Patients with type 1 diabetes saw blood sugars improve with liraglutide

July 2, 2018
Researchers from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo have found that adding liraglutide to insulin treatment for patients with type 1 diabetes results not only in better blood ...

Diabetes drug lowers risk of cardiovascular complications, kidney disease

June 13, 2016
Researchers have shown that the glucose-lowering drug liraglutide safely and effectively decreases the overall risk of heart attack, stroke, or cardiovascular death for people with type 2 diabetes. These patients are at high ...

Excess cardiac risk varies with age of onset of T1DM

August 31, 2018
(HealthDay)—Excess cardiovascular risk varies with age at diagnosis of type 1 diabetes, according to a study published online Aug. 27 in The Lancet.

Recommended for you

Researchers study abnormal blood glucose levels of discharged patients

December 14, 2018
University of Minnesota Medical School researchers decided to delve into an area where little data currently exists. They wanted to know what happens after these patients with abnormal blood glucose measurements are discharged? ...

Researchers zero in on potential therapeutic target for diabetes, associated diseases

December 14, 2018
A recent study led by researchers in Texas A&M University's department of nutrition and food science shows how a novel regulatory mechanism serves as an important biomarker for the development of diabetes, as well as a potential ...

Does diabetes damage brain health?

December 14, 2018
(HealthDay)—Diabetes has been tied to a number of complications such as kidney disease, but new research has found that older people with type 2 diabetes can also have more difficulties with thinking and memory.

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Millions of low-risk people with diabetes may be testing their blood sugar too often

December 10, 2018
For people with Type 2 diabetes, the task of testing their blood sugar with a fingertip prick and a drop of blood on a special strip of paper becomes part of everyday life.

Very low calorie diets trialled by NHS to tackle diabetes

December 7, 2018
Hundreds of thousands of people will receive NHS help to battle obesity and type 2 diabetes under radical action set out by Simon Stevens, Chief Executive of NHS England.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.